Molecular modulation of calcium oxalate crystallization

American Journal of Physiology - Renal Physiology

Volumn 291, Issue 6, 2006, Pages

  De Yoreo, James J ^a   Qiu, S Roger ^a   Hoyer, John R ^b,c  

^a LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF DELAWARE   (United States)

Author keywords

Atomic force microscopy; Biomineralization; Citrate; Kidney stone; Osteopontin

Indexed keywords

ASPARTIC ACID; CALCIUM ION; CALCIUM OXALATE; CITRIC ACID; OSTEOPONTIN; WHEWELLITE;

ATOMIC FORCE MICROSCOPY; BINDING SITE; BIOMINERALIZATION; CRYSTAL STRUCTURE; CRYSTALLIZATION; CRYSTALLOGRAPHY; HUMAN; KINETICS; MOLECULAR MODEL; NEPHROLITHIASIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN URINE LEVEL; REVIEW; STEREOCHEMISTRY; STONE FORMATION;

EID: 33845371361     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00136.2006     Document Type: Review

References (77)

1. Addadi L and Weiner S. Interactions between acidic proteins and crystals: stereochemical requirements in biomineralization. Proc Natl Acad Sci USA 82: 4110-4114, 1985.
2. Asplin JR, Arsenault D, Parks JH, Coe FL, and Hoyer JR. Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int 53: 194-199, 1998.
3. Asplin J, Deganello S, Nakagawa Y, and Coe FL. Evidence that nephrocalcin and urine inhibit nucleation of calcium oxalate monohydrate crystals. Am J Physiol Renal Fluid Electrolyte Physiol 261: F824-F830, 1991.
4. Asplin JR, Parks JH, Chen MS, Lieske JC, Toback FG, Pillay SN, Nakagawa Y, and Coe FL. Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int 56: 1505-1516, 1999.
5. Asplin JR, Parks JH, and Coe FL. Dependence of upper limit of metastability on supersaturation in nephrolithiasis. Kidney Int 52: 1602-1608, 1997.
6. Atmani F, Mizon J, and Khan SR. Identification of uronic-acid-rich protein as urinary bikunin, the light chain of inter-alpha-inhibitor. Eur J Biochem 236: 984-990, 1996.
7. Belcher AM, Wu XH, Christensen RJ, Hansma PK, Stucky GD, and Morse DE. Control of crystal phase switching and orientation by soluble mollusc-shell proteins. Nature 381: 56-58, 1996.
8. Berman A, Addadi L, and Weiner S. Interactions of sea-urchin skeleton macromolecules with growing calcite crystals - a study of intracrystalline proteins. Nature 331: 546-548, 1988.
9. Cabrera N and Vermilyea DA. Growth of crystals from solution. In: Growth and Perfection of Crystals; Proceedings, edited by Doremus RH, Roberts BW, and Turnbull D. New York: Wiley, 1958, p. 393-410.
10. Cody AM, Horner HT, and Cody RD. SEM study of the fine surface features of synthetic calcium oxalate monohydrate crystals. Scanning Electron Microsc: 185-197, 1982.
11. Coe FL, Parks JH, and Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 327: 1141-1152, 1992.
12. 2+ in calcite growth. Science 290: 1134-1137, 2000.
13. Deganello S and Piro O. The crystal structure of calcium oxalate monohydrate (whewellite). Neues JB Miner Monat 2: 81-88, 1981.
14. De Yoreo JJ and Dove PM. Shaping crystals with biomolecules. Science 306: 1301-1302, 2004.
15. De Yoreo JJ, Orme CA, and Land TA. Using atomic force microscopy to investigate solution crystal growth. In: Advances in Crystal Growth Research, edited by Sato K, Nakajima K, and Furukawa Y. Amsterdam: Elsevier, 2001, p. 361-380.
16. De Yoreo JJ and Vekilov P. Principles of crystal nucleation and growth. Rev Minerol Geochem 54: 57-93, 2003.
17. Dove PM, DeYoreo JJ, and Weiner S. Biomineralization. Rev Minerol Geochem 54: 1-381, 2003.
18. Edyvane KA, Hibberd CM, Harnett RM, Marshall VR, and Ryall RL. Macromolecules inhibit calcium oxalate crystal growth and aggregation in whole urine. Clin Chim Acta 167: 329-338, 1987.
19. Fisher LW, Hawkins GR, Tuross N, and Termine JD. Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. J Biol Chem 262: 9702-9708, 1987.
20. Fisher LW, Torchia DA, Fohr B, Young MF, and Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 280: 460-465, 2001.
21. Fu G, Qiu SR, Orme CA, Morse DE, and De Yoreo JJ. Acceleration of calcite kinetics by abalone nacre proteins. Adv Mater 17: 2678-2683, 2005.
22. Galosy R, Clark L, Ward DL, and Pak CYC. Renal oxalate excretion in calcium urolithiasis. J Urol 123: 320-323, 1980.
23. Gotliv BA, Kessler N, Sumerel JL, Morse DE, Tuross N, Addadi L, and Weiner S. Asprich: a novel aspartic acid-rich protein family from the prismatic shell matrix of the bivalve Atrina rigida. Chembiochem 6: 304-314, 2005.
24. Guo S, Ward MD, and Wesson JA. Direct visualization of calcium oxalate monohydrate crystallization and dissolution with atomic force microscopy and the role of polymeric additives. Langmuir 18: 4284-4291, 2002.
25. Hess B, Nakagawa Y, and Coe FL. Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol Renal Fluid Electrolyte Physiol 257: F99-F106, 1989.
26. Hess B, Zipperle L, and Jaeger P. Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol Renal Fluid Electrolyte Physiol 265: F784-F791, 1993.
27. Hoyer JR, Asplin JR, and Otvos L Jr. Phosphorylated osteopontin peptides suppress crystallization by inhibiting growth of calcium oxalate crystals. Kidney Int 60: 77-82, 2001.
28. Hoyer JR, Otvos L Jr, and Urge L. Role of osteopontin in urinary stone formation. Ann NY Acad Sci 760: 257-265, 1995.
29. Hoyer JR, Pietrzyk RA, Liu H, and Whitson PA. Effects of microgravity on urinary osteopontin. J Am Soc Nephrol 10: S389-S393, 1999.
30. Hunter GK, Kyle CL, and Goldberg HA. Modulation of crystal formation by bone phosphoproteins; structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J 300: 723-728, 1994.
31. Jung T, Sheng X, Choi CK, Kim WS, Wesson JA, and Ward MD. Probing crystallization of calcium oxalate monohydrate and the role of macromolecule additives with in situ atomic force microscopy. Langmuir 20: 8587-8596, 2004.
32. Kasugai S, Todescan R, Nagata T, Yao KL, Butler WT, and Sodek J. Expression of bone matrix proteins associated with mineralized tissue formation by adult rat bone marrow cells in vitro: inductive effects of dexamethasone on the osteoblastic phenotype. J Cell Physiol 147: 111-120, 1991.
33. Kohri K, Suzuki Y, Yoshida K, Yamamoto K, Amasaki N, Yamate T, Umekawa T, Iguchi M, Sinohara H, and Kurita T. Molecular cloning and sequencing of cDNA encoding urinary stone protein, which is identical to osteopontin. Biochem Biophys Res Commun 184: 859-864, 1992.
34. Kok DJ, Papapoulos SE, and Bijvoet OLM. Excessive crystal agglomeration with low citrate excretion in recurrent stone formers. Lancet i: 1056-1058, 1986.
35. Land TA and De Yoreo JJ. In situ AFM investigation of growth source activity on single crystals of canavalin. J Cryst Growth 208: 623-637, 1999.
36. Land TA, De Yoreo JJ, and Lee JD. An in situ AFM investigation of canavalin crystallization kinetics. Surface Sci 384: 136-155, 1997.
37. Land TA, Martin TL, Potapenko S, Palmore GT, and De Yoreo JJ. Recovery of surfaces from impurity poisoning during crystal growth. Nature 399: 442-445, 1999.
38. Lieske JC, Leonard R, and Toback FG. Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibited by specific anions. Am J Physiol Renal Fluid Electrolyte Physiol 268: F604-F612, 1995.
39. Lowenstam H and Weiner S. On Biomineralization. New York: Oxford Univ. Press, 1989, p. 324.
40. Mann S. Biomineralization: Principles and Concepts in Bioinorganic Materials Chemistry. New York: Oxford Univ. Press, 2001, p. 198.
41. McKee MD, Nanci A, and Khan SR. Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. J Bone Miner Res 10: 1913-1929, 1995.
42. Meyer JL and Smith LH. Growth of calcium oxalate crystals. II. Inhibition by natural urinary crystal growth inhibitors. Invest Urol 13: 36-39, 1975.
43. Millan A. Crystal growth shape of whewellite polymorphs: influence of structure distortions on crystal shape. Crystal Growth Des 1: 245-254, 2001.
44. Min W, Shiraga H, Chalko C, Goldfarb S, Krishna GG, and Hoyer JR. Quantitative studies of human urinary excretion of uropontin. Kidney Int 53: 189-193, 1998.
45. Mo L, Huang HY, Zhu XH, Shapiro E, Hasty DL, and Wu XR. Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int 66: 1159-1166, 2004.
46. Nagata T, Bellows CG, Kasugai S, Butler WT, and Sodek J. Biosynthesis of bone proteins [SPP-1 (secreted phosphoprotein-1, osteopontin), BSP (bone sialoprotein) and SPARC (osteonectin)] in association with mineralized-tissue formation by fetal-rat calvarial cells in culture. Biochem J 274: 513-520, 1991.
47. Nakagawa Y, Abram V, Kezdy FJ, Kaiser ET, and Coe FL. Purification and characterization of the principal inhibitor of calcium oxalate monohydrate crystal growth in human urine. J Biol Chem 258: 12594-12600, 1983.
48. Navrotsky A. Energetic clues to pathways to biomineralization: precursors, clusters and nanoparticles. Proc Nat Acad Sci USA 101: 12096-12101, 2004.
49. Nicar MJ, Hill K, and Pak CYC. Inhibition of spontaneous precipitation of calcium oxalate in vitro. J Bone Miner Res 2: 215-220, 1987.
50. Oldberg A, Franzen A, and Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 83: 8819-8823, 1986.
51. Orme CA, Noy A, Wierzbicki A, McBride MY, Grantham M, Dove PM, and DeYoreo JJ. Formation of chiral morphologies through selective binding of amino acids to calcite surface steps. Nature 411: 775-779, 2001.
52. Pak CYC. Citrate and renal calculi: an update. Miner Electrolyte Metab 20: 371-377, 1994.
53. Pillay SN, Asplin JR, and Coe FL. Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization. Am J Physiol Renal Physiol 275: F255-F261, 1998.
54. Prince CW, Oosawa T, Butler WT, Tomana M, Bhown AS, Bhown M, and Schrohenloher RE. Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chem 262: 2900-2907, 1987.
55. Qiu SR, Wierzbicki A, Orme CA, Cody AM, Hoyer JR, Nancollas GH, Zepeda S, and DeYoreo JJ. Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. Proc Nat Acad Sci USA 101: 1811-1815, 2004.
56. Qiu SR, Wierzbicki A, Salter A, Zepeda S, Orme CA, Hoyer JR, Nancollas GH, Cody AM, and De Yoreo JJ. Modulation of calcium oxalate monohydrate crystallization by citrate molecules through selective binding to atomic steps. J Am Chem Soc 127: 9036-9044, 2005.
57. Robertson WG, Peacock M, and Nordin BEC. Calcium crystalluria in recurrent renal stone formers. Clin Sci (Colch) 34: 579-594, 1968.
58. Robertson WG and Peacock M. Calcium oxalate crystalluria and inhibitors of crystallization in recurrent renal stone formers. Clin Sci (Colch) 43: 499-506, 1972.
59. Sheng X, Ward MD, and Wesson JA. Adhesion between molecules and calcium oxalate crystals: critical interactions in kidney stone formation. J Am Chem Soc 125: 2854-2855, 2003.
60. Shiraga H, Min W, VanDusen WJ, Clayman MD, Miner D, Terrell CH, Sherbotie JR, Foreman JW, Przysiecki C, Neilson EG, and Hoyer JR. Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 89: 426-430, 1992.
61. Singh K, DeVouge MW, and Mukherjee BB. Physiological properties and differential glycosylation of phosphorylated and nonphosphorylated forms of osteopontin secreted by normal rat kidney cells. J Biol Chem 265: 18696-18701, 1990.
62. Sorensen ES, Hojrup P, and Petersen TE. Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci 4: 2040-2049, 1995.
63. Stapleton AM and Ryall RL. Blood coagulation proteins and urolithiasis are linked: crystal matrix protein is the F1 activation peptide of human prothrombin. Br J Urol 75: 712-719, 1995.
64. Teng H, Dove PM, Orme C, and DeYoreo JJ. Thermodynamics of calcite growth: baseline for understanding biomineral formation. Science 282: 724-727, 1998.
65. Walters DA, Smith BL, Belcher AM, Paloczi GT, Stucky GD, Morse DE, and Hansma PK. Modification of calcite crystal growth by abalone shell proteins: an atomic force microscope study. Biophys J 72: 1425-1433, 1997.
66. Wang L, De Yoreo JJ, Zhang W, Guan X, Qiu SR, Hoyer JR, and Nancollas GH. Constant composition studies verify the utility of the Cabrera-Vermilyea (C-V) model in explaining mechanisms of calcium oxalate monohydrate crystallization. Crystal Growth Des 6: 1769-1775, 2006.
67. Wang L, Zhang W, Qiu SR, Zachowicz WJ, Guan X, Tang R, Hoyer JR, De Yoreo JJ, and Nancollas GH. Inhibition of calcium oxalate monohydrate crystallization by the combination of citrate and osteopontin. J Crystal Growth 291: 160-165, 2006.
68. Weaver M, Qiu SR, Hoyer JR, Casey WH, Nancollas GH, and De Yoreo JJ. Improved model for inhibition of pathological mineralization based on citrate-calcium oxalate monohydrate interaction. Chemphyschem. In press.
69. Webb MA. Cell-mediated crystallization of calcium oxalate in plants. Plant Cell 11: 751-761, 1999.
70. Wesson JA, Johnson RJ, Mazzali M, Beshensky AM, Steitz S, Giachelli CM, Liaw L, Alpers CE, Couser WG, Kleinman JG, and Hughes J. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 14: 139-147, 2003.
71. Wesson JA and Worcester E. Formation of hydrated calcium oxalates in the presence of poly-L-aspartic acid. Scanning Microsc 10: 415-424, 1996.
72. Wesson JA, Worcester EM, Wiessner JH, Mandel NS, and Kleinman JG. Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney Int 53: 952-957, 1998.
73. Wierzbicki A, Sikes CS, Sallis JD, Madura JD, Stevens ED, and Martin KL. Scanning electron microscopy and molecular modeling of calcium oxalate monohydrate crystal growth inhibition by citrate and phosphocitrate. Calcif Tissue Int 56: 297-304, 1995.
74. Wierzbicki A, Taylor MS, Knight CA, Madura JD, Harrington JP, and Sikes CS. Analysis of short-horn sculpin antifreeze protein stereospecific binding to (2-10) faces of ice. Biophys J 71: 8-18, 1996.
75. Worcester EM and Beshensky AM. Osteopontin inhibits nucleation of calcium oxalate crystals. Ann NY Acad Sci 760: 375-377, 1995.
76. Worcester EM, Nakagawa Y, Wabner CL, Kumar S, and Coe FL. Crystal adsorption and growth slowing by nephrocalcin, albumin, and Tamm-Horsfall protein. Am J Physiol Renal Fluid Electrolyte Physiol 255: F1197-F1205, 1988.
77. Worms D and Weiner S. Mollusk shell organic matrix: Fourier transform infrared study of the acidic macromolecules. J Exp Zool 237: 11-20, 1986.